drugset
drugset / Press release

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTÉGÉ, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

2009-06-16 · MacroGenics · original macrogenics.com ↗

Teplizumab

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTÉGÉ, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes 15.4 KB

The release as fetched from its publisher. macrogenics.com ↗